Pricing Log in Create free account

ALX Oncology Holdings Inc. (ALXO) vs Cue Biopharma, Inc. (CUE)

ALX Oncology Holdings Inc. and Cue Biopharma, Inc. are both Biotechnology companies. ALX Oncology Holdings Inc. and Cue Biopharma, Inc. are of similar size ($138.3M and $135.6M). ALX Oncology Holdings Inc. has the higher net margin (0.00% vs −435.8%) and the lower return on invested capital (−673.3% vs 0.00%). Across the 16 metrics below, ALX Oncology Holdings Inc. leads on 9 and Cue Biopharma, Inc. on 7.

Valuation

Metric ALXO CUE Biotechnology median
P/E n/m n/m 8.42
P/S 55.64 3.14 10.01
P/B 1.00 51.25 2.21
Price to free cash flow n/m n/m 21.01
EV/EBITDA n/m n/m 0.61
EV/Sales 5.06 2.73 9.41
Earnings yield (113.00%) (144.73%) (31.85%)
Free cash flow yield (52.28%) (42.34%) (24.58%)

Profitability

Metric ALXO CUE Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (262.03%) 0.00%
Net margin 0.00% (435.83%) 0.00%
Free cash flow margin 0.00% (133.13%) 0.00%
Return on equity (80.65%) (1,603.48%) (56.36%)
Return on assets (63.16%) (459.60%) (48.04%)
Return on invested capital (673.30%) 0.00% 0.00%

Growth

Metric ALXO CUE Biotechnology median
Revenue growth (TTM) — 354.37% 6.02%
EPS growth (last fiscal year) 26.36% 61.11% 30.26%
Revenue growth, 5-year CAGR — 54.16% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALXO CUE Biotechnology median
Debt to equity 0.07 0.00 0.00
Current ratio 9.71 1.25 4.72
Net debt to EBITDA 0.34 1.10 0.96

Dividend

Metric ALXO CUE Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric ALXO CUE Biotechnology median
Market cap 138.28m 135.63m 132.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack